Wellbutrin XL

See also: Generic Wellbutrin, Generic Wellbutrin SR

Wellbutrin XL is a brand name of bupropion, approved by the FDA in the following formulation(s):

WELLBUTRIN XL (bupropion hydrochloride - tablet, extended release; oral)

• 
  Manufacturer: VALEANT INTL
  
  Approval date: August 28, 2003
  
  Strength(s): 150MG ^[RLD][AB3], 300MG ^[AB3]

Has a generic version of Wellbutrin XL been approved?

A generic version of Wellbutrin XL has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Wellbutrin XL and have been approved by the FDA:

bupropion hydrochloride tablet, extended release; oral

• 
  Manufacturer: ACTAVIS
  
  Approval date: August 15, 2008
  
  Strength(s): 300MG ^[AB3]


• 
  Manufacturer: ACTAVIS
  
  Approval date: November 26, 2008
  
  Strength(s): 150MG ^[AB3]


• 
  Manufacturer: ANCHEN PHARMS
  
  Approval date: December 14, 2006
  
  Strength(s): 150MG ^[AB3], 300MG ^[AB3]


• 
  Manufacturer: IMPAX LABS
  
  Approval date: December 15, 2006
  
  Strength(s): 300MG ^[AB3]


• 
  Manufacturer: IMPAX LABS
  
  Approval date: November 26, 2008
  
  Strength(s): 150MG ^[AB3]


• 
  Manufacturer: MYLAN
  
  Approval date: July 14, 2010
  
  Strength(s): 150MG ^[AB3], 300MG ^[AB3]


• 
  Manufacturer: WATSON LABS
  
  Approval date: June 13, 2007
  
  Strength(s): 300MG ^[AB3]


• 
  Manufacturer: WATSON LABS
  
  Approval date: November 26, 2008
  
  Strength(s): 150MG ^[AB3]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Wellbutrin XL. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Delayed release tablet of bupropion hydrochloride
  Patent 6,096,341
  Issued: August 1, 2000
  Inventor(s): Seth; Pawan
  Assignee(s): Pharma Pass LLC
  The invention provides a controlled release tablet, free of stabilizer and free of pore-forming agent comprising: (i) a core consisting essentially of bupropion hydrochloride, a binder and a lubricant; and (ii) a coating consisting essentially of a water-insoluble, water-permeable film-forming polymer, a plasticizer and a water-soluble polymer.
  
  Patent expiration dates:
  
  
  • October 30, 2018
    
  
  

See also...

• Wellbutrin XL Extended-Release Tablets Consumer Information (Wolters Kluwer)
• Wellbutrin XL Consumer Information (Cerner Multum)
• Wellbutrin XL Advanced Consumer Information (Micromedex)
• Bupropion Consumer Information (Drugs.com)
• Bupropion Consumer Information (Wolters Kluwer)
• Bupropion Extended-Release Tablets Consumer Information (Wolters Kluwer)
• Bupropion Hydrobromide Extended-Release Tablets Consumer Information (Wolters Kluwer)
• Bupropion Sustained-Release Tablets Consumer Information (Wolters Kluwer)
• Bupropion Consumer Information (Cerner Multum)
• Bupropion Advanced Consumer Information (Micromedex)
• Bupropion Hydrochloride AHFS DI Monographs (ASHP)